CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
dual anti-platelet therapy +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05567562
NCT05567562Phase 2Completed
CompareCT.gov

Dual Anti-platelet Therapy in Chronic Obstructive Pulmonary Disease Study

Brigham and Women's Hospital·interventional·Posted Oct 5, 2022·Updated May 14, 2026

In Brief

A Phase 2 clinical trial evaluating dual anti-platelet therapy and Placebo for COPD and 2 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD, Emphysema, Emphysema or COPD
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedOct 5, 2022
Enrollment StartMar 27, 2024
Primary CompletionFeb 28, 2025
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.7 years ago

Interventions

dual anti-platelet therapycombination

dual anti-platelet therapy

Placebodrug

Placebo